---
title: "Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) | SVRA Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286808518.md"
description: "Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) | SVRA Stock News"
datetime: "2026-05-18T10:55:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286808518.md)
  - [en](https://longbridge.com/en/news/286808518.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286808518.md)
---

# Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) | SVRA Stock News

Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) | SVRA Stock News

### Related Stocks

- [SVRA.US](https://longbridge.com/en/quote/SVRA.US.md)

## Related News & Research

- [REGENXBIO Advances Duchenne Gene Therapy Toward Accelerated Approval](https://longbridge.com/en/news/286443456.md)
- [Sarepta's Elevidys Faces 'Little' Pressure After Regenxbio Data, Wedbush Says](https://longbridge.com/en/news/286589741.md)
- [14:05 ETLupin Receives Tentative Approval from U.S. FDA for Revefenacin Inhalation Solution](https://longbridge.com/en/news/286805922.md)
- [12:06 ETGenScript Launches TurboCHO™ Protein Expression Kit, Delivering the Fastest Path to Antibodies in its Class](https://longbridge.com/en/news/286130384.md)
- [Vast Therapeutics Presents Late-Breaking Phase 1 Data for Inhaled Therapy ALX1 at ATS 2026](https://longbridge.com/en/news/286795160.md)